Progesterone receptor signaling in the initiation of pregnancy and preservation of a healthy uterus

International Journal of Developmental Biology

Volumn 58, Issue 2-4, 2014, Pages 95-106

  Wetendorf, Margeaux ^a   DeMayo, Francesco J ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Early pregnancy; Mouse model; Progesterone receptor; Progesterone signaling

Indexed keywords

CYCLOOXYGENASE 2; MIFEPRISTONE; NUCLEAR RECEPTOR COACTIVATOR; PROGESTERONE RECEPTOR; PROGESTERONE RECEPTOR MODULATOR;

BINDING AFFINITY; BREAST CANCER; CANCER HORMONE THERAPY; CELL MIGRATION; DECIDUALIZATION; DNA BINDING; DRUG EFFICACY; DRUG RESPONSE; ENDOMETRIAL DISEASE; ENDOMETRIOSIS; ENDOMETRIUM CANCER; FEMALE INFERTILITY; FIRST TRIMESTER PREGNANCY; GENE TARGETING; HOX GENE; HUMAN; IMPLANTATION; LEIOMYOMA; LIGAND BINDING; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PREGNANCY OUTCOME; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN STRUCTURE; REPRODUCTIVE SUCCESS; REVIEW; UPREGULATION; UTERINE CERVIX DISEASE; UTERUS BLEEDING; UTERUS FUNCTION; ANIMAL; ANIMAL EMBRYO; FEMALE; METABOLISM; NIDATION; PHYSIOLOGY; PREGNANCY; UTERUS;

ANIMALS; EMBRYO IMPLANTATION; EMBRYO, MAMMALIAN; FEMALE; HUMANS; PREGNANCY; PREGNANCY MAINTENANCE; RECEPTORS, PROGESTERONE; UTERUS;

EID: 84904214477     PISSN: 02146282     EISSN: None     Source Type: Journal    
DOI: 10.1387/ijdb.140069mw     Document Type: Review

References (112)

1. ABDEL-HAFIZ, H., DUDEVOIR, M.L. and HORWITZ, K.B. (2009). Mechanisms underlying the control of progesterone receptor transcriptional activity by SUMOylation. J Biol Chem 284: 9099-9108.
2. ABDEL-HAFIZ, H.A. and HORWITZ, K.B. (2014). Post-translational modifcations of the progesterone receptors. J Steroid Biochem Mol Biol 140: 80-89.
3. ANGERS, S. and MOON, R.T. (2009). Proximal events in Wnt signal transduction. Nat Rev Mol Cell Biol 10: 468-477.
4. ARNETT-MANSFIELD, R.L., DEFAZIO, A., WAIN, G.V., JAWORSKI, R.C., BYTH, K., MOTE, P.A. and CLARKE, C.L. (2001). Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium. Cancer Res 61: 4576-4582.
5. BARENT, R.L., NAIR, S.C., CARR, D.C., RUAN, Y., RIMERMAN, R.A., FULTON, J., ZHANG, Y. and SMITH, D.F. (1998). Analysis of FKBP51/FKBP52 chimeras and mutants for Hsp90 binding and association with progesterone receptor complexes. Mol Endocrinol 12: 342-354.
6. BELLANCE, C., KHAN, J.A., MEDURI, G., GUIOCHON-MANTEL, A., LOMBES, M. and LOOSFELT, H. (2013). Progesterone receptor isoforms PRA and PRB differentially contribute to breast cancer cell migration through interaction with focal adhesion kinase complexes. Mol Biol Cell 24: 1363-1374.
7. BENSON, G.V., LIM, H., PARIA, B.C., SATOKATA, I., DEY, S.K. and MAAS, R.L. (1996). Mechanisms of reduced fertility in Hoxa-10 mutant mice: uterine homeosis and loss of maternal Hoxa-10 expression. Development 122: 2687-2696.
8. BOKHMAN, J.V. (1983). Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15: 10-17.
9. BOONYARATANAKORNKIT, V., SCOTT, M.P., RIBON, V., SHERMAN, L., ANDERSON, S.M., MALLER, J.L., MILLER, W.T. and EDWARDS, D.P. (2001). Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. Mol Cell 8: 269-280.
10. BROSENS, J.J., TULLET, J., VARSHOCHI, R. and LAM, E.W. (2004). Steroid receptor action. Best Pract Res Clin Obstet Gynaecol 18: 265-283.
11. CARBONELL ESTEVE, J.L., ACOSTA, R., HEREDIA, B., PEREZ, Y., CASTANEDA, M.C. and HERNANDEZ, A.V. (2008). Mifepristone for the treatment of uterine leiomyomas: a randomized controlled trial. Obstet Gynecol 112: 1029-1036.
12. CARSON, D.D., BAGCHI, I., DEY, S.K., ENDERS, A.C., FAZLEABAS, A.T., LESSEY, B.A. and YOSHINAGA, K. (2000). Embryo implantation. Dev Biol 223: 217-237.
13. CHA, J., SUN, X. and DEY, S.K. (2012). Mechanisms of implantation: strategies for successful pregnancy. Nat Med 18: 1754-1767.
14. CHABBERT-BUFFET, N., MEDURI, G., BOUCHARD, P. and SPITZ, I.M. (2005). Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum Reprod Update 11: 293-307.
15. CHEUNG-FLYNN, J., PRAPAPANICH, V., COX, M.B., RIGGS, D.L., SUAREZ-QUIAN, C. and SMITH, D.F. (2005). Physiological role for the cochaperone FKBP52 in androgen receptor signaling. Mol Endocrinol 19: 1654-1666.
16. CHWALISZ, K., DEMANNO, D., GARG, R., LARSEN, L., MATTIA-GOLDBERG, C. and STICKLER, T. (2004). Therapeutic potential for the selective progesterone receptor modulator asoprisnil in the treatment of leiomyomata. Semin Reprod Med 22: 113-119.
17. CHWALISZ, K., LARSEN, L., MATTIA-GOLDBERG, C., EDMONDS, A., ELGER, W. and WINKEL, C.A. (2007). A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertil Steril 87: 1399-1412.
18. CHWALISZ, K., PEREZ, M.C., DEMANNO, D., WINKEL, C., SCHUBERT, G. and ELGER, W. (2005). Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev 26: 423-438.
19. CLEMM, D.L., SHERMAN, L., BOONYARATANAKORNKIT, V., SCHRADER, W.T., WEIGEL, N.L. and EDWARDS, D.P. (2000). Differential hormone-dependent phos-phorylation of progesterone receptor A and B forms revealed by a phosphoserine site-specific monoclonal antibody. Mol Endocrinol 14: 52-65.
20. CONDON, J.C., HARDY, D.B., KOVARIC, K. and MENDELSON, C.R. (2006). Up-regulation of the progesterone receptor (PR)-C isoform in laboring myometrium by activation of nuclear factor-kappaB may contribute to the onset of labor through inhibition of PR function. Mol Endocrinol 20: 764-775.
21. CONNEELY, O.M., KETTELBERGER, D.M., TSAI, M.J., SCHRADER, W.T. and O'malley, B.W. (1989). The chicken progesterone receptor A and B isoforms are products of an alternate translation initiation event. J Biol Chem 264: 14062-14064.
22. CRAMER, S.F. and PATEL, A. (1990). The frequency of uterine leiomyomas. Am J Clin Pathol 94: 435-438.
23. DANIEL, A.R., GAVIGLIO, A.L., CZAPLICKI, L.M., HILLARD, C.J., HOUSA, D. and LANGE, C.A. (2010). The progesterone receptor hinge region regulates the kinetics of transcriptional responses through acetylation, phosphorylation, and nuclear retention. Mol Endocrinol 24: 2126-2138.
24. DEMAYO, F.J., ZHAO, B., TAKAMOTO, N. and TSAI, S.Y. (2002). Mechanisms of action of estrogen and progesterone. Ann N Y Acad Sci 955: 48-59; discussion 86-48, 396-406.
25. EHRLICH, C.E., YOUNG, P.C., STEHMAN, F.B., SUTTON, G.P. and ALFORD, W.M. (1988). Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. Am J Obstet Gynecol 158: 796-807.
26. ELLMANN, S., STICHT, H., THIEL, F., BECKMANN, M.W., STRICK, R. and STRIS-SEL, P.L. (2009). Estrogen and progesterone receptors: from molecular structures to clinical targets. Cell Mol Life Sci 66: 2405-2426.
27. FISCELLA, K., EISINGER, S.H., MELDRUM, S., FENG, C., FISHER, S.G. and GUZICK, D.S. (2006). Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstet Gynecol 108: 1381-1387.
28. FRANCO, H.L., DAI, D., LEE, K.Y., RUBEL, C.A., ROOP, D., BOERBOOM, D., JEONG, J.W., LYDON, J.P., BAGCHI, I.C., BAGCHI, M.K. et al., (2011). WNT4 is a key regulator of normal postnatal uterine development and progesterone signaling during embryo implantation and decidualization in the mouse. Faseb J 25: 1176-1187.
29. FRANCO, H.L., RUBEL, C.A., LARGE, M.J., WETENDORF, M., FERNANDEZ-VALDIVIA, R., JEONG, J.W., SPENCER, T.E., BEHRINGER, R.R., LYDON, J.P. and DEMAYO, F.J. (2012). Epithelial progesterone receptor exhibits pleiotropic roles in uterine development and function. Faseb J 26: 1218-1227.
30. FUJIMOTO, J., ICHIGO, S., HORI, M., NISHIGAKI, M. and TAMAYA, T. (1995). Expression of progesterone receptor form A and B mRNAs in gynecologic malignant tumors. Tumour Biol 16: 254-260.
31. GELLERSEN, B., FERNANDES, M.S. and BROSENS, J.J. (2009). Non-genomic progesterone actions in female reproduction. Hum Reprod Update 15: 119-138.
32. GENDRON, R.L., PARADIS, H., HSIEH-LI, H.M., LEE, D.W., POTTER, S.S. and MAR-KOFF, E. (1997). Abnormal uterine stromal and glandular function associated with maternal reproductive defects in Hoxa-11 null mice. Biol Reprod 56: 1097-1105.
33. GIANGRANDE, P.H., KIMBREL, E.A., EDWARDS, D.P. and MCDONNELL, D.P. (2000). The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding. Mol Cell Biol 20: 3102-3115.
34. GIANGRANDE, P.H., POLLIO, G. and MCDONNELL, D.P. (1997). Mapping and characterization of the functional domains responsible for the differential activity of the A and B isoforms of the human progesterone receptor. J Biol Chem 272: 32889-32900.
35. GIUDICE, L.C. and KAO, L.C. (2004). Endometriosis. Lancet 364: 1789-1799.
36. GRONEMEYER, H. (1991). Transcription activation by estrogen and progesterone receptors. Annu Rev Genet 25: 89-123.
37. GRONEMEYER, H., TURCOTTE, B., QUIRINSTRICKER, C., BOCQUEL, M.T., MEYER, M.E., KROZOWSKI, Z., JELTSCH, J.M., LEROUGE, T., GARNIER, J.M. and CHAMBON, P. (1987). The chicken progesterone receptor: sequence, expression and functional analysis. Embo J 6: 3985-3994.
38. GUIOCHON-MANTEL, A., LOOSFELT, H., LESCOP, P., SAR, S., ATGER, M., PERROT-APPLANAT, M. and MILGROM, E. (1989). Mechanisms of nuclear localization of the progesterone receptor: evidence for interaction between monomers. Cell 57: 1147-1154.
39. GUNDERSON, C.C., FADER, A.N., CARSON, K.A. and BRISTOW, R.E. (2012). Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol 125: 477-482.
40. HAM, J., THOMSON, A., NEEDHAM, M., WEBB, P. and PARKER, M. (1988). Characterization of response elements for androgens, glucocorticoids and progestins in mouse mammary tumour virus. Nucleic Acids Res 16: 5263-5276.
41. HANNA, R., PANG, Y., THOMAS, P. and ZHU, Y. (2006). Cell-surface expression, progestin binding, and rapid nongenomic signaling of zebrafsh membrane pro-gestin receptors alpha and beta in transfected cells. J Endocrinol 190: 247-260.
42. HERRMANN, W., WYSS, R., RIONDEL, A., PHILIBERT, D., TEUTSCH, G., SAKIZ, E. and BAULIEU, E.E. (1982). [The effects of an antiprogesterone steroid in women: interruption of the menstrual cycle and of early pregnancy]. C R Seances Acad Sci III 294: 933-938.
43. HOEKSTRA, A.V., SEFTON, E.C., BERRY, E., LU, Z., HARDT, J., MARSH, E., YIN, P., CLARDY, J., CHAKRAVARTI, D., BULUN, S. et al., (2009). Progestins activate the AKT pathway in leiomyoma cells and promote survival. J Clin Endocrinol Metab 94: 1768-1774.
44. HSUEH, A.J., PECK, E.J., Jr. and Clark, J.H. (1975). Progesterone antagonism of the oestrogen receptor and oestrogen-induced uterine growth. Nature 254: 337-339.
45. ISHIKAWA, H., ISHI, K., SERNA, V.A., KAKAZU, R., BULUN, S.E. and KURITA, T. (2010). Progesterone is essential for maintenance and growth of uterine leiomyoma. Endocrinology 151: 2433-2442.
46. KAKU, T., YOSHIKAWA, H., TSUDA, H., SAKAMOTO, A., FUKUNAGA, M., KU-WABARA, Y., HATAEG, M., KODAMA, S., KUZUYA, K., SATO, S. et al., (2001). Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome. Cancer Lett 167: 39-48.
47. KARTERIS, E., ZERVOU, S., PANG, Y., DONG, J., HILLHOUSE, E.W., RANDEVA, H.S. and THOMAS, P. (2006). Progesterone signaling in human myometrium through two novel membrane G protein-coupled receptors: potential role in functional progesterone withdrawal at term. Mol Endocrinol 20: 1519-1534.
48. KASTNER, P., KRUST, A., TURCOTTE, B., STROPP, U., TORA, L., GRONEMEYER, H. and CHAMBON, P. (1990). Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. Embo J 9: 1603-1614.
49. KETTEL, L.M., MURPHY, A.A., MORALES, A.J., ULMANN, A., BAULIEU, E.E. and YEN, S.S. (1996). Treatment of endometriosis with the antiprogesterone mife-pristone (RU486). Fertil Steril 65: 23-28.
50. KIM, J.J., KURITA, T. and BULUN, S.E. (2013). Progesterone action in endometrial cancer, endometriosis, uterine fbroids, and breast cancer. Endocr Rev 34: 130-162.
51. KUMAR, N.S., RICHER, J., OWEN, G., LITMAN, E., HORWITZ, K.B. and LESLIE, K.K. (1998). Selective down-regulation of progesterone receptor isoform B in poorly differentiated human endometrial cancer cells: implications for unopposed estrogen action. Cancer Res 58: 1860-1865.
52. KUMAR, V. and CHAMBON, P. (1988). The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer. Cell 55: 145-156.
53. KURIHARA, I., LEE, D.K., PETIT, F.G., JEONG, J., LEE, K., LYDON, J.P., DEMAYO, F.J., TSAI, M.J. and TSAI, S.Y. (2007). COUP-TFII mediates progesterone regulation of uterine implantation by controlling ER activity. PLoS Genet 3: e102.
54. LAMMINEN, S., RANTALA, I., HELIN, H., RORARIUS, M. and TUIMALA, R. (1992). Proliferative activity of human uterine leiomyoma cells as measured by automatic image analysis. Gynecol Obstet Invest 34: 111-114.
55. LEE, K., JEONG, J., KWAK, I., YU, C.T., LANSKE, B., SOEGIARTO, D.W., TOFTGARD, R., TSAI, M.J., TSAI, S., LYDON, J.P. et al., (2006). Indian hedgehog is a major mediator of progesterone signaling in the mouse uterus. Nat Genet 38: 1204-1209.
56. LEE, K.Y., JEONG, J.W., WANG, J., MA, L., MARTIN, J.F., TSAI, S.Y., LYDON, J.P. and DEMAYO, F.J. (2007). Bmp2 is critical for the murine uterine decidual response. Mol Cell Biol 27: 5468-5478.
57. LI, Q., KANNAN, A., DEMAYO, F.J., LYDON, J.P., COOKE, P.S., YAMAGISHI, H., SRIVASTAVA, D., BAGCHI, M.K. and BAGCHI, I.C. (2011). The antiproliferative action of progesterone in uterine epithelium is mediated by Hand2. Science 331: 912-916.
58. LIM, H., MA, L., MA, W.G., MAAS, R.L. and DEY, S.K. (1999). Hoxa-10 regulates uterine stromal cell responsiveness to progesterone during implantation and decidualization in the mouse. Mol Endocrinol 13: 1005-1017.
59. LYDON, J.P., DEMAYO, F.J., FUNK, C.R., MANI, S.K., HUGHES, A.R., MONTGOMERY, C.A., Jr., SHYAMALA, G., CONNEELY, O.M. and O'malley, B.W. (1995). Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev 9: 2266-2278.
60. MANI, S.K., ALLEN, J.M., LYDON, J.P., MULAC-JERICEVIC, B., BLAUSTEIN, J.D., DEMAYO, F.J., CONNEELY, O. and O'malley, B.W. (1996). Dopamine requires the unoccupied progesterone receptor to induce sexual behavior in mice. Mol Endocrinol 10: 1728-1737.
61. MCKENNA, N.J. and O'malley, B.W. (2002). Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 108: 465-474.
62. MEYER, M.E., PORNON, A., JI, J.W., BOCQUEL, M.T., CHAMBON, P. and GRONE-MEYER, H. (1990). Agonistic and antagonistic activities of RU486 on the functions of the human progesterone receptor. Embo J 9: 3923-3932.
63. MOTE, P.A., BALLEINE, R.L., MCGOWAN, E.M. and CLARKE, C.L. (1999). Colo-calization of progesterone receptors A and B by dual immunofuorescent histo-chemistry in human endometrium during the menstrual cycle. J Clin Endocrinol Metab 84: 2963-2971.
64. MUKHERJEE, A., SOYAL, S.M., FERNANDEZ-VALDIVIA, R., GEHIN, M., CHAMBON, P., DEMAYO, F.J., LYDON, J.P. and O'malley, B.W. (2006). Steroid receptor coactivator 2 is critical for progesterone-dependent uterine function and mammary morphogenesis in the mouse. Mol Cell Biol 26: 6571-6583.
65. MULAC-JERICEVIC, B. and CONNEELY, O.M. (2004). Reproductive tissue selective actions of progesterone receptors. Reproduction 128: 139-146.
66. MULAC-JERICEVIC, B., LYDON, J.P., DEMAYO, F.J. and CONNEELY, O.M. (2003). Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform. Proc Natl Acad Sci USA 100: 9744-9749.
67. MULAC-JERICEVIC, B., MULLINAX, R.A., DEMAYO, F.J., LYDON, J.P. and CON-NEELY, O.M. (2000). Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform. Science 289: 1751-1754.
68. OLIVE, D.L. and PRITTS, E.A. (2001). Treatment of endometriosis. N Engl J Med 345: 266-275.
69. PARKER, W.H. (2007). Etiology, symptomatology, and diagnosis of uterine myomas. Fertil Steril 87: 725-736.
70. PEREIRA, F.A., QIU, Y., ZHOU, G., TSAI, M.J. and TSAI, S.Y. (1999). The orphan nuclear receptor COUP-TFII is required for angiogenesis and heart development. Genes Dev 13: 1037-1049.
71. PRATT, W.B. and TOFT, D.O. (1997). Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev 18: 306-360.
72. RAMIREZ, P.T., FRUMOVITZ, M., BODURKA, D.C., SUN, C.C. and LEVENBACK, C. (2004). Hormonal therapy for the management of grade 1 endometrial adeno-carcinoma: a literature review. Gynecol Oncol 95: 133-138.
73. RAMONDETTA, L.M., JOHNSON, A.J., SUN, C.C., ATKINSON, N., SMITH, J.A., JUNG, M.S., BROADDUS, R., IYER, R.B. and BURKE, T. (2009). Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma. Cancer 115: 1867-1874.
74. RUBEL, C.A., LANZ, R.B., KOMMAGANI, R., FRANCO, H.L., LYDON, J.P. and DE-MAYO, F.J. (2012). Research resource: Genome-wide profiling of progesterone receptor binding in the mouse uterus. Mol Endocrinol 26: 1428-1442.
75. SAITO, S., ITO, K., NAGASE, S., SUZUKI, T., AKAHIRA, J., OKAMURA, K., YAEGASHI, N. and SASANO, H. (2006). Progesterone receptor isoforms as a prognostic marker in human endometrial carcinoma. Cancer Sci 97: 1308-1314.
76. SAKAGUCHI, H., FUJIMOTO, J., HONG, B.L., NAKAGAWA, Y. and TAMAYA, T. (2004). Drastic decrease of progesterone receptor form B but not A mRNA reflects poor patient prognosis in endometrial cancers. Gynecol Oncol 93: 394-399.
77. SAMALECOS, A. and GELLERSEN, B. (2008). Systematic expression analysis and antibody screening do not support the existence of naturally occurring progesterone receptor (PR)-C, PR-M, or other truncated PR isoforms. Endocrinology 149: 5872-5887.
78. SARTORIUS, C.A., MELVILLE, M.Y., HOVLAND, A.R., TUNG, L., TAKIMOTO, G.S. and HORWITZ, K.B. (1994). A third transactivation function (AF3) of human progesterone receptors located in the unique N-terminal segment of the B-isoform. Mol Endocrinol 8: 1347-1360.
79. SHERMAN, M.E. (2000). Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol 13: 295-308.
80. SIEGEL, R., WARD, E., BRAWLEY, O. and JEMAL, A. (2011). Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236.
81. SITRUK-WARE, R. (2004). Pharmacological profile of progestins. Maturitas 47: 277-283.
82. SMITH, C.L. and O'malley, B.W. (2004). Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 25: 45-71.
83. SMITH, J.L., KUPCHAK, B.R., GARITAONANDIA, I., HOANG, L.K., MAINA, A.S., REGALLA, L.M. and LYONS, T.J. (2008). Heterologous expression of human mPRalpha, mPRbeta and mPRgamma in yeast confirms their ability to function as membrane progesterone receptors. Steroids 73: 1160-1173.
84. SMITH, W.L., GARAVITO, R.M. and DEWITT, D.L. (1996). Prostaglandin endoper-oxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 271: 33157-33160.
85. SOYAL, S.M., MUKHERJEE, A., LEE, K.Y., LI, J., LI, H., DEMAYO, F.J. and LYDON, J.P. (2005). Cre-mediated recombination in cell lineages that express the progesterone receptor. Genesis 41: 58-66.
86. SPITZ, I.M. (2003). Progesterone antagonists and progesterone receptor modulators: an overview. Steroids 68: 981-993.
87. SPITZ, I.M. (2009). Clinical utility of progesterone receptor modulators and their effect on the endometrium. Curr Opin Obstet Gynecol 21: 318-324.
88. STEPHEN, E.H. and CHANDRA, A. (2000). Use of infertility services in the United States: 1995. Fam Plann Perspect 32: 132-137.
89. SUN, H.S., HSIAO, K.Y., HSU, C.C., WU, M.H. and TSAI, S.J. (2003). Transactivation of steroidogenic acute regulatory protein in human endometriotic stromalcells is mediated by the prostaglandin EP2 receptor. Endocrinology 144: 3934-3942.
90. TAKAMOTO, N., KURIHARA, I., LEE, K., DEMAYO, F.J., TSAI, M.J. and TSAI, S.Y. (2005). Haploinsuffciency of chicken ovalbumin upstream promoter transcription factor II in female reproduction. Mol Endocrinol 19: 2299-2308.
91. TAYLOR, H.S., ARICI, A., OLIVE, D. and IGARASHI, P. (1998). HOXA10 is expressed in response to sex steroids at the time of implantation in the human endometrium. J Clin Invest 101: 1379-1384.
92. TAYLOR, H.S., IGARASHI, P., OLIVE, D.L. and ARICI, A. (1999). Sex steroids mediate HOXA11 expression in the human peri-implantation endometrium. J Clin Endocrinol Metab 84: 1129-1135.
93. THIGPEN, J.T., BRADY, M.F., ALVAREZ, R.D., ADELSON, M.D., HOMESLEY, H.D., MANETTA, A., SOPER, J.T. and GIVEN, F.T. (1999). Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 17: 1736-1744.
94. TRANGUCH, S., CHEUNG-FLYNN, J., DAIKOKU, T., PRAPAPANICH, V., COX, M.B., XIE, H., WANG, H., DAS, S.K., SMITH, D.F. and DEY, S.K. (2005). Cochaperone immunophilin FKBP52 is critical to uterine receptivity for embryo implantation. Proc Natl Acad Sci USA 102: 14326-14331.
95. TRANGUCH, S., WANG, H., DAIKOKU, T., XIE, H., SMITH, D.F. and DEY, S.K. (2007). FKBP52 deficiency-conferred uterine progesterone resistance is genetic background and pregnancy stage specific. J Clin Invest 117: 1824-1834.
96. USHIJIMA, K., YAHATA, H., YOSHIKAWA, H., KONISHI, I., YASUGI, T., SAITO, T., NAKANISHI, T., SASAKI, H., SAJI, F., IWASAKA, T. et al., (2007). Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol 25: 2798-2803.
97. VEGETO, E., SHAHBAZ, M.M., WEN, D.X., GOLDMAN, M.E., O'malley, B.W. and MCDONNELL, D.P. (1993). Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. Mol Endocrinol 7: 1244-1255.
98. VERCELLINI, P., CORTESI, I. and CROSIGNANI, P.G. (1997). Progestins for symptomatic endometriosis: a critical analysis of the evidence. Fertil Steril 68: 393-401.
99. VICENT, G.P., NACHT, A.S., ZAURIN, R., FONT-MATEU, J., SORONELLAS, D., LE DILY, F., REYES, D. and BEATO, M. (2013). Unliganded progesterone receptor-mediated targeting of an RNA-containing repressive complex silences a subset of hormone-inducible genes. Genes Dev 27: 1179-1197.
100. WANG, H. and DEY, S.K. (2006). Roadmap to embryo implantation: clues from mouse models. Nat Rev Genet 7: 185-199.
101. WEI, L.L., HAWKINS, P., BAKER, C., NORRIS, B., SHERIDAN, P.L. and QUINN, P.G. (1996). An amino-terminal truncated progesterone receptor isoform, PRc, enhances progestin-induced transcriptional activity. Mol Endocrinol 10: 1379-1387.
102. WEI, L.L. and MINER, R. (1994). Evidence for the existence of a third progesterone receptor protein in human breast cancer cell line T47D. Cancer Res 54: 340-343.
103. WEI, L.L., NORRIS, B.M. and BAKER, C.J. (1997). An N-terminally truncated third progesterone receptor protein, PR(C), forms heterodimers with PR(B) but interferes in PR(B)-DNA binding. J Steroid Biochem Mol Biol 62: 287-297.
104. WHITNEY, C.W., BRUNETTO, V.L., ZAINO, R.J., LENTZ, S.S., SOROSKY, J., ARMSTRONG, D.K. and LEE, R.B. (2004). Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92: 4-9.
105. WILCOX, L.S., KOONIN, L.M., POKRAS, R., STRAUSS, L.T., XIA, Z. and PETERSON, H.B. (1994). Hysterectomy in the United States, 1988-1990. Obstet Gynecol 83: 549-555.
106. XU, J., QIU, Y., DEMAYO, F.J., TSAI, S.Y., TSAI, M.J. and O'malley, B.W. (1998). Partial hormone resistance in mice with disruption of the steroid receptor coactiva-tor-1 (SRC-1) gene. Science 279: 1922-1925.
107. YAMADA, T., NAKAGO, S., KURACHI, O., WANG, J., TAKEKIDA, S., MATSUO, H. and MARUO, T. (2004). Progesterone down-regulates insulin-like growth factor-I expression in cultured human uterine leiomyoma cells. Hum Reprod 19: 815-821.
108. ZHANG, Y., BECK, C.A., POLETTI, A., CLEMENT, J.P.T., PRENDERGAST, P., YIP, T.T., HUTCHENS, T.W., EDWARDS, D.P. and WEIGEL, N.L. (1997). Phosphoryla-tion of human progesterone receptor by cyclin-dependent kinase 2 on three sites that are authentic basal phosphorylation sites in vivo. Mol Endocrinol 11: 823-832.
109. ZHANG, Y., BECK, C.A., POLETTI, A., EDWARDS, D.P. and WEIGEL, N.L. (1994). Identification of phosphorylation sites unique to the B form of human progesterone receptor. In vitro phosphorylation by casein kinase II. J Biol Chem 269: 31034-31040.
110. ZHANG, Y., BECK, C.A., POLETTI, A., EDWARDS, D.P. and WEIGEL, N.L. (1995). Identification of a group of Ser-Pro motif hormone-inducible phosphorylation sites in the human progesterone receptor. Mol Endocrinol 9: 1029-1040.
111. ZHU, Y., BOND, J. and THOMAS, P. (2003a). Identification, classification, and partial characterization of genes in humans and other vertebrates homologous to a fish membrane progestin receptor. Proc Natl Acad Sci USA 100: 2237-2242.
112. ZHU, Y., RICE, C.D., PANG, Y., PACE, M. and THOMAS, P. (2003b). Cloning, expression, and characterization of a membrane progestin receptor and evidence it is an intermediary in meiotic maturation of fish oocytes. Proc Natl Acad Sci USA 100: 2231-2236.